Zomedica Corp. [ZOM] Stock trading around $0.48 per share: What’s Next?

Zomedica Corp. [AMEX: ZOM] stock went on an upward path that rose over 21.00% on Friday, amounting to a one-week price increase of more than 109.89%. The company report on January 4, 2021 that Zomedica Appoints Robert Cohen CEO as Company Nears Commercialization of TRUFORMA™.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced the appointment of Robert Cohen as Chief Executive Officer effective January 1, 2021. Mr. Cohen previously served as the Company’s Interim CEO and as a member of the Board of Directors.

Mr. Cohen brings to Zomedica more than 30 years of executive leadership and operations experience from the medical device, biotechnology and pharmaceutical industries. Following his earlier tenure at three multi-billion-dollar medical technology companies, Mr. Cohen built shareholder value at a series of smaller organizations as Chief Executive Officer. The Board of Directors recruited Mr. Cohen due to his successful track record in building early-stage companies and developing and launching a series of medical devices and biotechnology products. Mr. Cohen will continue to drive the completion of the development and commercialization of the Company’s TRUFORMA™ point-of-care diagnostic platform.

Over the last 12 months, ZOM stock rose by 51.39%. The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $225.60 million, with 550.54 million shares outstanding and 539.13 million shares in the current float. Compared to the average trading volume of 79.09M shares, ZOM stock reached a trading volume of 286354759 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Zomedica Corp. [ZOM]:

The Average True Range (ATR) for Zomedica Corp. is set at 0.05 The Price to Book ratio for the last quarter was 6.05, with the Price to Cash per share for the same quarter was set at 0.11.

ZOM Stock Performance Analysis:

Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 109.89. With this latest performance, ZOM shares gained by 181.56% in over the last four-week period, additionally plugging by 187.92% over the last 6 months – not to mention a rise of 51.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 81.92, with the RSI for the last a single of trading hit 83.45, and the three-weeks RSI is set at 80.32 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.1727, while it was recorded at 0.4166 for the last single week of trading, and 0.1590 for the last 200 days.

Insight into Zomedica Corp. Fundamentals:

Return on Total Capital for ZOM is now -687.86, given the latest momentum, and Return on Invested Capital for the company is -687.85. Return on Equity for this stock declined to -687.85, with Return on Assets sitting at -387.30.

Reflecting on the efficiency of the workforce at the company, Zomedica Corp. [ZOM] managed to generate an average of -$706,573 per employee.Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.60 and a Current Ratio set at 25.60.

ZOM Stock EPS

With the latest financial reports released by the company, Zomedica Corp. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.

Zomedica Corp. [ZOM] Insider Position Details

There are presently around $16 million, or 8.50% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. with ownership of 12,254,080, which is approximately 0% of the company’s market cap and around 4.42% of the total institutional ownership; VANGUARD GROUP INC, holding 10,776,155 shares of the stock with an approximate value of $5.22 million in ZOM stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $1.39 million in ZOM stock with ownership of nearly 192.053% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Zomedica Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 23 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 9,857,776 shares. Additionally, 11 investors decreased positions by around 2,145,719 shares, while 5 investors held positions by with 20,617,461 shares. The mentioned changes placed institutional holdings at 32,620,956 shares, according to the latest SEC report filing. ZOM stock had 13 new institutional investments in for a total of 2,419,663 shares, while 9 institutional investors sold positions of 1,391,816 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam